Lineage Cell Therapeutics
LCTX
105 hedge funds and large institutions have $52.1M invested in Lineage Cell Therapeutics in 2018 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 18 increasing their positions, 71 reducing their positions, and 16 closing their positions.
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
0% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 16
1% less funds holding
Funds holding: 106 → 105 (-1)
5.05% less ownership
Funds ownership: 50% → 44.95% (-5%)
60% less capital invested
Capital invested by funds: $130M → $52.1M (-$78.3M)
75% less repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 71
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Investments
New York
|
+$558K |
| 2 |
Renaissance Technologies
New York
|
+$397K |
| 3 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$177K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$161K |
| 5 |
JG
Jefferies Group
New York
|
+$130K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadwood Capital
New York
|
-$6.57M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$4.77M |
| 3 |
Axa
Paris,
France
|
-$1.82M |
| 4 |
BlackRock
New York
|
-$1.22M |
| 5 |
Bank of New York Mellon
New York
|
-$713K |
LCTX Hedge Fund Activity: Q4 2018 in Review
105 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Lineage Cell Therapeutics (LCTX) for Q4 2018, worth a combined $52.1M — down 60% from $130M a quarter earlier.
Fund positioning in LCTX was balanced in Q4 2018: 16 funds opened new positions, 16 closed out, 18 added to existing stakes and 71 trimmed.
The largest buyer was Two Sigma Investments, adding an estimated $558K. The largest seller was Broadwood Capital, cutting an estimated $6.57M.
- 105 institutional investors held Lineage Cell Therapeutics (LCTX) as of Q4 2018, down from 106 in Q3 2018.
- Funds reported $52.1M of Lineage Cell Therapeutics stock for Q4 2018, down 60% quarter-over-quarter.
- 16 funds opened new Lineage Cell Therapeutics positions in Q4 2018 and 16 closed out, a net change of 0 holders.
- The largest Lineage Cell Therapeutics buyer in Q4 2018 was Two Sigma Investments, an estimated $558K added.
- The largest Lineage Cell Therapeutics seller in Q4 2018 was Broadwood Capital, an estimated $6.57M sold.
Based on aggregated 13F filings for Q4 2018.